Keywords: hybridon, cmv, antisense, therapy, europe, plans, start

Hybridon To Test CMV Antisense Therapy In Europe

Article | 01 July 1996

Print This

Hybridon plans to start clinical trials in August with its genetic antisense drug, GEM 132, for the treatment of cytomegalovirus retinitis ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in